Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
Clinical trial NCT02970942 · COMPLETED
Trial details
- NCT number
- NCT02970942
- Sponsor
- Novo Nordisk A/S
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-30
- Primary completion
- 2020-02-13
- Enrollment
- 320
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.